19 research outputs found
Low extracellular vesicle concentrations predict survival in patients with heart failure
BackgroundHeart disease is of worldwide importance due to high morbidity and mortality. Extracellular vesicle (EV) concentration and size represent novel diagnostic and prognostic biomarkers, e.g. in patients with liver cancer, but data on their prognostic relevance in heart disease are lacking. Here, we investigated the role of EV concentration, size and zeta potential in patients with heart disease.MethodsVesicle size distribution, concentration and zeta potential were measured by nanoparticle tracking analysis (NTA) in 28 intensive care unit (ICU) and 20 standard care (SC) patients and 20 healthy controls.ResultsPatients with any disease had a lower zeta potential compared to the healthy controls. Vesicle size (X50) was significantly higher in ICU patients (245â
nm) with heart disease as compared to those patients with heart disease receiving standard care (195â
nm), or healthy controls (215â
nm) (pâ=â0.001). Notably, EV concentration was lower in ICU patients with heart disease (4.68âĂâ1010 particles/ml) compared to SC patients with heart disease (7,62âĂâ1010 particles/ml) and healthy controls (1.50âĂâ1011 particles/ml) (pâ=â0.002). Extracellular vesicle concentration is prognostic for overall survival in patients with heart disease. Overall survival is significantly reduced when the vesicle concentration is below 5.55âĂâ1010 particles/ml. Median overall survival was only 140 days in patients with vesicle concentrations below 5.55âĂâ1010 particles/ml compared to 211 days in patients with vesicle concentrations above 5.55âĂâ1010 particles/ml (pâ=â0.032).SummaryConcentration of EVs is a novel prognostic marker in ICU and SC patients with heart disease
Primat der Lust. Gesellschaftlicher Wandel des Sexuellen und die Erosion genuiner Sexualmoral
Lewandowski S. Primat der Lust. Gesellschaftlicher Wandel des Sexuellen und die Erosion genuiner Sexualmoral. In: Haubeck W, Heinrichs W, eds. SexualitĂ€t â Geschenk und Verantwortung. Theologische Impulse. Vol 25. Witten: SCM; 2013
Recommended from our members
The ânew normalâ for UK theatre?
The global pandemic put a sudden hold on the world, and while different economies and industries are slowly firing up again trying to get back to normal business, most theatres remain closed. In fact, theatre and other forms of live entertainment are among those industries that have suffered the most and stayed closed for longest. But theatre is innovative, creative and eager to thrive. From prerecorded online releases over live-streamed performances to drive-in theatre, the industry is desperate to find ways to survive until social distancing guidance allows venues to reopen to economically viable numbers of audience members
Recommended from our members
Keeping in touch with your audience during a global pandemic
The audience is the heart and soul of theatre. In the time of Shakespeare or even during the Roman Empire, if the audience didn't like the performance enough to show up, the curtain wouldn't rise. Today it wouldn't be as drastic, but the audience's power is still undeniable. Productions have shut down early because of poor ticket sales. Without an audience, a production can't break even, let alone make a return on its investment. When creating a new theatre, a key factor is audience response to plots, characters -and depending on the genre- songs. Are they relatable? Is the audience going to care about them? Will they keep the audience engaged
Sarcopenia and Myosteatosis as Prognostic Markers in Patients with Advanced Cholangiocarcinoma Undergoing Palliative Treatment
Background: Cholangiocarcinoma (CCA) represents the second most common primary liver cancer and is characterized by a very poor outcome, but reliable prognostic markers are largely missing. Sarcopenia, the progressive loss of muscle mass and strength, as well as myosteatosis have been associated with an unfavorable outcome in several clinical conditions, including cancer. Here, we evaluated the prognostic relevance of sarcopenia and myosteatosis using routine abdominal CT (computed tomography) scans in advanced stage CCA patients undergoing palliative treatment. Methods: Routine abdominal CT scans were used to assess the skeletal muscle and the psoas muscle index (L3SMI/L3PMI) at the level of the third lumbar vertebra as radiological indices for sarcopenia as well as the mean skeletal muscle attenuation (MMA) as a surrogate for myosteatosis. Results were correlated with clinical data and outcomes. Results: Using a calculated optimal cut-off value of 71.95 mm2/cm, CCA patients with an L3SMI value below this cut-off showed a significantly reduced median overall survival (OS) of only 250 days compared to 450 days in patients with a higher L3SMI. Moreover, the median OS of CCA patients with an L3PMI above 6345 mm2/cm was 552 days compared to 252 days in patients with a lower L3PMI. Finally, CCA patients with an MMA above 30.51 Hounsfield Units survived significantly longer (median OS: 430 days) compared to patients with an MMA value below this ideal cut-off (median OS: 215 days). The prognostic relevance of L3SMI, L3PMI, and MMA was confirmed in uni- and multivariate Cox regression analyses. Conclusion: Routine abdominal CT scans represent a unique opportunity to evaluate sarcopenia as well as myosteatosis in advanced CCA patients. We identified the L3SMI/L3PMI as well as the MMA as negative prognostic factors in CCA patients undergoing palliative therapy, arguing that the âopportunisticâ evaluation of these parameters might yield important clinical information in daily routine
Bone Mineral Density Is a Predictor of Mortality in Female Patients with Cholangiocellular Carcinoma Undergoing Palliative Treatment
Background: Cholangiocellular adenocarcinoma (CCA) is a rare and aggressive malignancy originating from the bile ducts. Its general prognosis is poor as therapeutic options are limited. Many patients present with advanced stages of disease, and palliative chemotherapy remains the only treatment option. Prognostic markers to assess the outcome of chemotherapeutic treatment in CCA are limited. We therefore evaluated bone mineral density (BMD) as a prognostic tool in patients with advanced CCA. Patients and Methods: We included 75 patients with advanced CCA that were treated at our academic tumor center. Prior to treatment, bone mineral density was analyzed at the first lumbar vertebra using routine CT scans in the venous phase and the local PACS (IntelliSpace PACS, Philips, Amsterdam, The Netherlands). Results: BMD was not significantly different between male and female patients but decreased with age. Patients with BMD above 167 HU have a significantly improved overall survival (474 days vs. 254 days; log-rank X2(1) = 6.090; p = 0.014). The prognostic value of BMD was confirmed using univariate (HR 2.313 (95%CI: 1.170â4.575); p = 0.016) and multivariate (HR 4.143 (95%CI: 1.197â14.343); p = 0.025) Cox regression analyses. Subgroup analysis revealed that the prognostic value of BMD was only present in female patients and not in male patients, suggesting sex-specific differences. Conclusions: Our data suggest that BMD is a valuable, easily accessible, and independent prognostic marker for overall survival in patients with advanced CCA. Furthermore, subgroup analysis showed the sex specificity of this marker, which demonstrated relevance only in female patients